Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prophylactic Donor Lymphocyte Infusion (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Small Molecules, Cell Therapies
- Administration
- Intravenous
01
Overview
Prophylactic Donor Lymphocyte Infusion (DLI) is a cellular immunotherapy protocol developed by the Chinese PLA General Hospital to prevent disease relapse in patients with very high-risk hematologic malignancies, including leukemia and lymphoma, following allogeneic peripheral blood stem cell transplantation (allo-PBSCT). The intervention utilizes unmanipulated, G-CSF-primed donor-derived lymphocytes (specifically CD3+ cells) to induce a graft-versus-leukemia (GVL) effect, where donor immune cells recognize and eliminate residual malignant cells in the recipient. For patients harboring specific high-risk mutations such as TP53, TET2, or DNMT3a, the protocol incorporates the administration of decitabine, a hypomethylating agent, prior to the infusion to enhance the GVL effect and potentially sensitize tumor cells to immune-mediated destruction.
- Other names
- G-CSF-primed prophylactic DLIProphylactic DLI with decitabineDonor Lymphocyte Infusion-Chinese PLA General Hospital
Beyond the preview
Go deeper on Prophylactic Donor Lymphocyte Infusion (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prophylactic Donor Lymphocyte Infusion (Chinese PLA General Hospital).